ETRM needs to offer significant price inducements to plans like BS/BC and to out-of-pocket paying clients in the next 12 months. After that ETRM can gradually raise prices. The stock market likes nothing more than a sales /volume surprise.
Inns: You still believe the SEC actually enforces such things. Case in point: Shorts drove down the price of Encysive as low as .59, before the company was sold to Pfizer for 2.35, plus assumption of $130M debt. THREE MILLION "guaranteed delivery" shares were NEVER delivered. The SEC said NOTHING and 3 million shares were never covered.
Innsbrooklad: A number of companies have a tiny float after a R/S. PRO: Makes a short squeeze much easier(see CAPN). CON: If no positive news most times the R/S stock gets aggressively attacked(see CYTK). A common fallacy is that stocks that are difficult to borrow have limited or no short activity: Not true, as the pros naked short all the time and have sophisticated trading programs to mitigate a market that turns sharply against them.
Warren: If you don't like 28 employees, how does 50 strike you? In the last presentation mgmt. stated they are a 50-employee company.
Ade: Executives and board members should have shown optimism by collectively buying a few hundred thousand shares right after the positive FDA decision-they did not and the Market took notice. After a major event there is usually a window for executives and board members to buy in the Market(one of the few exceptions is if there is another imminent major event).
I pray that ETRM is planning some sort of positive PR by Monday market open to prevent the shares from breaking a buck.
As a long, I believe that ETRM, for a microcap, has an above average management team and BOD in terms of experience and expertise; however, I truly feel that mgmt. expected ETRM to be trading in the $4-5 range post FDA approval. Reluctantly they have had to resort to milking the ATM cow and a controlled rollout that perhaps is disappointing analysts, which created a downward stock price spiral. I once thought breaking a buck and a reverse stock split were pure fantasy-now I'm not so sure.
Why is it at $1.03? Every time there is an ATM dump it resets a base stock price lower. Per the latest 10K, in 2015 through March 13, ETRM sold $6.4 M worth of shares through Cowen(and almost certainly a further ATM dump on March 16). Normal large volume days should bring a price increase NOT a decrease, excepting ATM dump days.
ETRM management is mismanaging the ATM program, unnecessarily releasing to Cowen 500K to 1M share chunks to sell, instead of parceling out say 100K a day. This has to stop as ETRM management is liable to a lawsuit claiming fiduciary mismanagement.
I agree. Many missed a significant comment in the last presentation: "we are a 50-person company." This indicates a brisk employee ramp up as I believe the headcount in 2014 was only about 28. New people cost money.
Does anyone have any analyst sales estimates? ETrade's sales estimates are 1.5M, 8.7M, 30.8M, AND 53.1M for the respective years 2015-2018.
Apollo Endosurgery has raised $50 million from private equity investor Athyrium Capital Management mostly to repay debt it accrued when it acquired the Lap-Band from Allergan ($AGN) in December 2013 for up to $110 million. As part of that deal, Apollo also gained the intra-gastric balloon system Orbera, which isn't approved in the U.S.
Last year, the company rolled out an advertising campaign and a financing program to aid in promoting the Lap-Band. But the Lap-Band has been struggling in recent years after a 2011 study found that about one in three Lap-Band patients experienced band erosion with almost half of them requiring surgical removal of their bands. In addition, weight loss is less with the Lap-Band than with other forms of bariatric surgery.
Not one share of options has been exercised. "Exercised" means actually buying shares at the option exercise price. Greg Lea's Form 5 explanation for a 2012 "inadvertent sale" was woefully late and a bit fishy. He blames his bank for the error but does not buy back the shares.
Knudson is way too experienced to not have advanced partnership talks; also director Friedman is a former investment banker with Morgan Stanley. Greg Lea was very casual about future capital raises, probably because a potential cash-rich partner is waiting in the wings. With the dollar strong against the Australian dollar and Euro, I wonder if any centers in Australia and Europe/Middle East(especially Turkey)might try to promote a little medical tourism for VBLOC.
Greg Lea should have a UC Irvine doctor at his 4PM presentation. Dana Point is very close to Irvine. This is a make or break conference for ETRM. Many more analysts are in Dana Point than were in Boston for Knudson's recent subpar performance.
Ade: Jansz did NOT buy 175,000 shares. He already indirectly owned them as previously reported on 5/14/14. Please check your facts before posting.